MeiraGTx Holdings plc (MGTX)
NASDAQ: MGTX · IEX Real-Time Price · USD
5.09
+0.08 (1.60%)
Apr 19, 2024, 4:00 PM EDT - Market closed
MeiraGTx Holdings Market Cap
MeiraGTx Holdings has a market cap or net worth of $323.71 million as of April 19, 2024. Its market cap has increased by 24.31% in one year.
Market Cap
323.71M
Enterprise Value
282.32M
1-Year Change
24.31%
Ranking
Category
Stock Price
$5.09
Market Cap Chart
Since June 8, 2018, MeiraGTx Holdings's market cap has decreased from $407.80M to $323.71M, a decrease of -20.62%. That is a compound annual growth rate of -3.86%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
Apr 18, 2024 | 321.70M | -4.57% |
Apr 17, 2024 | 337.10M | -2.96% |
Apr 16, 2024 | 347.40M | -1.11% |
Apr 15, 2024 | 351.30M | -1.60% |
Apr 12, 2024 | 357.00M | -2.99% |
Apr 11, 2024 | 368.00M | 1.97% |
Apr 10, 2024 | 360.90M | -1.74% |
Apr 9, 2024 | 367.30M | 2.68% |
Apr 8, 2024 | 357.70M | 1.27% |
Apr 5, 2024 | 353.20M | -0.17% |
Apr 4, 2024 | 353.80M | 1.46% |
Apr 3, 2024 | 348.70M | -1.80% |
Apr 2, 2024 | 355.10M | -4.82% |
Apr 1, 2024 | 373.10M | -4.28% |
Mar 28, 2024 | 389.80M | -2.26% |
Mar 27, 2024 | 398.80M | 0.81% |
Mar 26, 2024 | 395.60M | -3.89% |
Mar 25, 2024 | 411.60M | 0.78% |
Mar 22, 2024 | 408.40M | -1.54% |
Mar 21, 2024 | 414.80M | -0.48% |
Mar 20, 2024 | 416.80M | 3.35% |
Mar 19, 2024 | 403.30M | 1.31% |
Mar 18, 2024 | 398.10M | -2.38% |
Mar 15, 2024 | 407.80M | 8.69% |
Mar 14, 2024 | 375.20M | -7.08% |
View and export this data all the way back to 2018.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
Atai Life Sciences | 332.04M |
Health Catalyst | 331.47M |
CVRx, Inc. | 329.17M |
Precigen | 327.33M |
Esperion Therapeutics | 327.20M |
Anavex Life Sciences | 324.97M |
Renovaro Biosciences | 323.25M |
Acrivon Therapeutics | 317.36M |